MYG1 Knockout NCI-H1703 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human MYG1 gene, encoding a mitochondrial 3′-5′ exonuclease. Derived from the NCI-H1703 lung squamous cell carcinoma cell line, this polyclonal pool maintains genetic heterogeneity while ensuring consistent MYG1 disruption. The use of CRISPR/Cas9 technology enables efficient gene disruption, allowing study of mitochondrial and cellular phenotypes without single-cell cloning. This model is suitable for investigating mitochondrial RNA processing and apoptosis regulation in cancer.
The host cell line NCI-H1703 is a well-characterized lung squamous cell carcinoma model derived from a 54-year-old male patient. It recapitulates key features of non-small cell lung cancer, particularly the squamous subtype, and is widely used for studying tumor biology, drug responses, and lung cancer mechanisms. This line harbors genetic alterations typical of lung squamous cell carcinomas, making it a relevant platform for gene function assessment. Introducing MYG1 knockout provides a tool to explore mitochondrial contributions to lung cancer pathogenesis.
At the molecular level, MYG1 functions as a mitochondrial 3′-5′ exonuclease that participates in RNA surveillance and processing. It interacts with PNPT1 and likely SUPV3L1, central components of the mitochondrial RNA degradosome. MYG1 activity stabilizes mitochondrial transcripts including MT-CO1 and MT-ND1, essential for respiratory chain function. Its disruption alters the BAX/BCL2 ratio, elevates ROS production, and modulates caspase-9 activation, thereby impacting the intrinsic apoptosis pathway. Thus, MYG1 connects mitochondrial gene expression to apoptotic regulation.
In NCI-H1703 lung cancer cells, MYG1 knockout is significant for studying the role of mitochondrial function in survival and drug resistance. Lung squamous cell carcinomas exhibit metabolic reprogramming and altered apoptosis; loss of MYG1 may sensitize cells to death stimuli or metabolic stress. The model allows examination of how mitochondrial RNA processing defects affect tumor fitness, potentially revealing therapeutic vulnerabilities. Furthermore, mitochondrial morphology and dynamics changes can be assessed in this polyclonal knockout population, offering insight into MYG1??s role in malignant mitochondrial homeostasis.
This polyclonal knockout product supports a range of applications including western blotting for BAX/BCL2, RT-qPCR for mitochondrial transcripts (e.g., MT-CO1, MT-ND1), and immunofluorescence for mitochondrial morphology. Functional studies can employ Annexin V apoptosis assays to evaluate cell death responses and Seahorse metabolic analysis to assess bioenergetics. These methods are valuable for investigating mitochondrial dysfunction, lung cancer drug resistance, apoptosis regulation, and mitochondrial RNA biology. For further information or assistance, please contact Ascent Research.
